Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFACute: Rifampicin in Cutibacterium Acnes Prosthetic Joint Infections
NCT05902221Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- May 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rifampicin in prosthetic joint infection (PJI) (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Rate of C. acnes prosthetic joint infections management failure at 24 months and Rate of adverse event linked to rifampicin. Started May 2024; status: recruiting.
02
Drugs
rifampicin
03
Conditions
prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT05902221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902221.